Lpath Initiates First-in-Human Dosing in Phase I Trial
Lpath, Inc. recently announced that the first cohort of six subjects has been dosed in the Phase I clinical trial with Lpathomab. The double-blind, placebo-controlled, single ascending dose trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Lpathomab in healthy volunteers. The trial also aims to establish a maximum tolerated dose for future clinical studies in patients with neuropathic pain. The trial will include a total of five cohorts at increasing doses.
“The dosing of our first subjects with Lpathomab is a significant milestone, and we are very pleased to begin the development of this important product candidate intended to treat neuropathic pain, which is an area of tremendous unmet medical need,” said Dario Paggiarino, MD, Lpath’s Senior Vice President, Chief Development Officer.
Lpathomab is an antibody-targeting lysophosphatidic acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath’s preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain, and pain associated with lumbosacral radiculopathy. Other preclinical studies have also demonstrated the potential for Lpathomab as a treatment for traumatic brain injury.
San Diego-based Lpath, Inc. is the category leader in lipid-targeted therapeutics. The company’s ImmuneY2 drug discovery engine has the unique ability to generate therapeutic antibodies that bind and inhibit bioactive lipids that contribute to disease. The company has developed four drug candidates, has advanced the first two to mid-stage trials, and built evidence to support its approach of targeting bioactive lipids to treat a wide range of diseases. For more information, visit www.Lpath.com.
Total Page Views: 761
